These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

542 related articles for article (PubMed ID: 32686647)

  • 1. Human DECR1 is an androgen-repressed survival factor that regulates PUFA oxidation to protect prostate tumor cells from ferroptosis.
    Nassar ZD; Mah CY; Dehairs J; Burvenich IJ; Irani S; Centenera MM; Helm M; Shrestha RK; Moldovan M; Don AS; Holst J; Scott AM; Horvath LG; Lynn DJ; Selth LA; Hoy AJ; Swinnen JV; Butler LM
    Elife; 2020 Jul; 9():. PubMed ID: 32686647
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 2,4-dienoyl-CoA reductase regulates lipid homeostasis in treatment-resistant prostate cancer.
    Blomme A; Ford CA; Mui E; Patel R; Ntala C; Jamieson LE; Planque M; McGregor GH; Peixoto P; Hervouet E; Nixon C; Salji M; Gaughan L; Markert E; Repiscak P; Sumpton D; Blanco GR; Lilla S; Kamphorst JJ; Graham D; Faulds K; MacKay GM; Fendt SM; Zanivan S; Leung HY
    Nat Commun; 2020 May; 11(1):2508. PubMed ID: 32427840
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A ferroptosis-inducing biomimetic nanocomposite for the treatment of drug-resistant prostate cancer.
    Chen J; Wang Y; Han L; Wang R; Gong C; Yang G; Li Z; Gao S; Yuan Y
    Mater Today Bio; 2022 Dec; 17():100484. PubMed ID: 36388460
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ACSM1 and ACSM3 Regulate Fatty Acid Metabolism to Support Prostate Cancer Growth and Constrain Ferroptosis.
    Shrestha RK; Nassar ZD; Hanson AR; Iggo R; Townley SL; Dehairs J; Mah CY; Helm M; Alizadeh-Ghodsi M; Pickering M; Ghesquière B; Watt MJ; Quek LE; Hoy AJ; Tilley WD; Swinnen JV; Butler LM; Selth LA
    Cancer Res; 2024 Jul; 84(14):2313-2332. PubMed ID: 38657108
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of dietary polyunsaturated fatty acids on castration-resistant Pten-null prostate cancer.
    Wang S; Wu J; Suburu J; Gu Z; Cai J; Axanova LS; Cramer SD; Thomas MJ; Perry DL; Edwards IJ; Mucci LA; Sinnott JA; Loda MF; Sui G; Berquin IM; Chen YQ
    Carcinogenesis; 2012 Feb; 33(2):404-12. PubMed ID: 22159221
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Darolutamide-mediated phospholipid remodeling induces ferroptosis through the SREBP1-FASN axis in prostate cancer.
    Li B; Cheng B; Huang H; Huang S; Yu S; Li Z; Peng S; Du T; Xie R; Huang H
    Int J Biol Sci; 2024; 20(12):4635-4653. PubMed ID: 39309439
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bufalin induces ferroptosis by modulating the 2,4-dienoyl-CoA reductase (DECR1)-SLC7A11 axis in breast cancer.
    Wu S; Wu X; Wang Q; Chen Z; Li L; Chen H; Qi H
    Phytomedicine; 2024 Dec; 135():156130. PubMed ID: 39427521
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapy-induced lipid uptake and remodeling underpin ferroptosis hypersensitivity in prostate cancer.
    Tousignant KD; Rockstroh A; Poad BLJ; Talebi A; Young RSE; Taherian Fard A; Gupta R; Zang T; Wang C; Lehman ML; Swinnen JV; Blanksby SJ; Nelson CC; Sadowski MC
    Cancer Metab; 2020; 8():11. PubMed ID: 32577235
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Peroxidation of polyunsaturated fatty acids by lipoxygenases drives ferroptosis.
    Yang WS; Kim KJ; Gaschler MM; Patel M; Shchepinov MS; Stockwell BR
    Proc Natl Acad Sci U S A; 2016 Aug; 113(34):E4966-75. PubMed ID: 27506793
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FAF1 blocks ferroptosis by inhibiting peroxidation of polyunsaturated fatty acids.
    Cui S; Simmons G; Vale G; Deng Y; Kim J; Kim H; Zhang R; McDonald JG; Ye J
    Proc Natl Acad Sci U S A; 2022 Apr; 119(17):e2107189119. PubMed ID: 35467977
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ATF6α promotes prostate cancer progression by enhancing PLA2G4A-mediated arachidonic acid metabolism and protecting tumor cells against ferroptosis.
    Zhao R; Lv Y; Feng T; Zhang R; Ge L; Pan J; Han B; Song G; Wang L
    Prostate; 2022 Apr; 82(5):617-629. PubMed ID: 35089606
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting ferroptosis as a vulnerability in pulmonary diseases.
    Yang L; Cao LM; Zhang XJ; Chu B
    Cell Death Dis; 2022 Jul; 13(7):649. PubMed ID: 35882850
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Elevation of androgen receptor promotes prostate cancer metastasis by induction of epithelial-mesenchymal transition and reduction of KAT5.
    Lin CY; Jan YJ; Kuo LK; Wang BJ; Huo C; Jiang SS; Chen SC; Kuo YY; Chang CR; Chuu CP
    Cancer Sci; 2018 Nov; 109(11):3564-3574. PubMed ID: 30142696
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Polyunsaturated fatty acids-induced ferroptosis suppresses pancreatic cancer growth.
    Suda A; Umaru BA; Yamamoto Y; Shima H; Saiki Y; Pan Y; Jin L; Sun J; Low YLC; Suzuki C; Abe T; Igarashi K; Furukawa T; Owada Y; Kagawa Y
    Sci Rep; 2024 Feb; 14(1):4409. PubMed ID: 38388563
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Estrogen induces androgen-repressed SOX4 expression to promote progression of prostate cancer cells.
    Yang M; Wang J; Wang L; Shen C; Su B; Qi M; Hu J; Gao W; Tan W; Han B
    Prostate; 2015 Sep; 75(13):1363-75. PubMed ID: 26015225
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Krüppel-like factor 8 is a novel androgen receptor co-activator in human prostate cancer.
    He HJ; Gu XF; Xu WH; Yang DJ; Wang XM; Su Y
    Acta Pharmacol Sin; 2013 Feb; 34(2):282-8. PubMed ID: 23023312
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CYLD regulates cell ferroptosis through Hippo/YAP signaling in prostate cancer progression.
    Gu Y; Wu S; Fan J; Meng Z; Gao G; Liu T; Wang Q; Xia H; Wang X; Wu K
    Cell Death Dis; 2024 Jan; 15(1):79. PubMed ID: 38246916
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ELOVL5 Is a Critical and Targetable Fatty Acid Elongase in Prostate Cancer.
    Centenera MM; Scott JS; Machiels J; Nassar ZD; Miller DC; Zinonos I; Dehairs J; Burvenich IJG; Zadra G; Chetta PM; Bango C; Evergren E; Ryan NK; Gillis JL; Mah CY; Tieu T; Hanson AR; Carelli R; Bloch K; Panagopoulos V; Waelkens E; Derua R; Williams ED; Evdokiou A; Cifuentes-Rius A; Voelcker NH; Mills IG; Tilley WD; Scott AM; Loda M; Selth LA; Swinnen JV; Butler LM
    Cancer Res; 2021 Apr; 81(7):1704-1718. PubMed ID: 33547161
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design and synthesis of isothiocyanate-containing hybrid androgen receptor (AR) antagonist to downregulate AR and induce ferroptosis in GSH-Deficient prostate cancer cells.
    Qin Z; Ou S; Xu L; Sorensen K; Zhang Y; Hu DP; Yang Z; Hu WY; Chen F; Prins GS
    Chem Biol Drug Des; 2021 May; 97(5):1059-1078. PubMed ID: 33470049
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel Strategy of Proxalutamide for the Treatment of Prostate Cancer through Coordinated Blockade of Lipogenesis and Androgen Receptor Axis.
    Gu Y; Xue M; Wang Q; Hong X; Wang X; Zhou F; Sun J; Wang G; Peng Y
    Int J Mol Sci; 2021 Dec; 22(24):. PubMed ID: 34948018
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 28.